On 27 October 2011, orphan designation (EU/3/11/925) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for mifepristone for the treatment of hypercortisolism (Cushing's syndrome) of endogenous origin.
The sponsorship was transferred to Dr Ulrich Granzer, Germany, in December 2012 and subsequently to FGK Representative Service GmbH, Germany, in October 2013 and to Dr Ulrich Granzer, Germany, in August 2015.
The sponsorship was transferred to Granzer Regulatory Consulting & Services GmbH, Germany in March 2022.
Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: